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Introduction
Endometrial cancer is among the three most common
cancers in females in many industrialized countries.
Known risk factors for this disease include obesity,
hypertension, diabetes mellitus, late menopause, and
exogenous estrogen use. Most of endometrial cancers
are sporadic, but it has been estimated that 5% of
patients with endometrial cancers diagnosed at age
younger than 55 years have a family history of this cancer,
i.e. hereditary origin [1].
Currently, two different pathways are distinguished
for tumorigenesis of sporadic endometrial carcinoma.
This dualistic model of endometrial tumorigenesis is
based on a hypothesis by Bokhman in 1983 [2], accord-
ing solely to clinical observations and clinicopathologic
correlations. The majority of sporadic endometrial carci-
nomas (at least approximately 70–80%), designated as
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SUMMARY
In 1983, Bokhman proposed a dualistic model of endometrial tumorigenesis based on the clinical observations
and clinicopathologic correlations. The majority of endometrial cancers (approximately 70–80%), designated
as type I carcinomas, follow the estrogen-related pathway. Histologically, most of the type I tumors seem to
arise in the background of hyperplastic endometrium, show an endometrioid differentiation, and are of low
grade. Clinically, they are overall characterized by a favorable behavior. Another 10–20% of endometrial cancers,
designated as type II carcinomas, follow the estrogen-unrelated pathway and arise in the background of atrophic
endometrium. Type II tumors usually occur at an older age, approximately 5–10 years later than type I tumors.
They are typically high-grade carcinomas of nonendometrioid differentiation, most frequently serous, less frequently
clear cell. Type II carcinomas behave as an aggressive clinical course and poor prognosis. This dualistic model
was subsequently supported by the molecular studies, approximately a decade later. At present, endometrioid
and serous carcinoma, which represent the major phenotypes of types I and II endometrial carcinomas, respectively,
are characterized by distinctive types of genetic instability and molecular alterations. In endometrioid (type I)
carcinoma, four major genetic changes are responsible for the tumorigenesis, i.e. silencing of PTEN tumor sup-
pressor gene, presence of microsatellite instability due to alterations of the mismatch repair genes, mutation of
K-ras protooncogene, and alteration of β-catenin gene. On the other hand, p53 mutation and overexpression
of Her2/neu oncogene are two major genetic alterations in serous and clear cell (type II) carcinomas. However, like
in any model, there is evidence for exceptions. Many endometrial carcinomas are in the gray zone with overlapping
clinical, morphologic, immunohistochemical, and molecular features of types I and II endometrial cancers. Finally,
a small group of endometrial carcinoma is noted to be hereditary. It is known as the most common extracolonic
malignancy in hereditary nonpolyposis colorectal cancer (Lynch syndrome), an autosomal dominantly inherited
disorder of cancer susceptibility. Inactivation of the mismatch repair genes MSH2 and MSH6 seems to play a
central role in the tumorigenesis. [Taiwanese J Obstet Gynecol 2007;46(1):26–32]
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type I carcinomas, follow the estrogen-related pathway.
They seem to arise in the background of unopposed
estrogenic stimulation [3], since they are associated with
endometrial hyperplasia, express estrogen (ER) and prog-
esterone receptors (PR) [4]. Histologically, most of the
type I tumors show endometrioid differentiation and
are of low grade. The rare mucinous adenocarcinomas
are also considered type I carcinomas, since they usually
express ER and/or PR and are of low histopathologic
grade. Clinically, type I carcinomas are overall character-
ized by a favorable behavior.
About 10–20% of sporadic endometrial carcinomas,
designated as type II carcinomas, follow the estrogen-
unrelated pathway and arise in the background of
atrophic endometrium [5]. ER and PR expression in
these tumors is usually negative or weakly positive.
Type II tumors usually occur at an older age, approxi-
mately 5–10 years later than type I tumors. They are
typically high-grade carcinomas of nonendometrioid
differentiation, most frequently serous, less frequently
clear cell. Both serous and clear cell carcinomas are fre-
quently associated with endometrial intraepithelial car-
cinoma (EIC), which is considered the putative precursor
for these tumors [6,7]. Type II carcinomas are character-
ized by an aggressive clinical course and poor prognosis.
The clinical and pathologic features of these two types
of endometrial cancer are summarized in Table 1.
The dualistic model was subsequently broadened
by the inclusion of molecular aspects, approximately a
decade later. At present, endometrioid and serous carci-
noma, which represent the major phenotypes of types I
and II endometrial carcinomas, respectively, are char-
acterized by distinctive types of genetic instability and
molecular alterations. However, like in any model, there
is evidence for exceptions. For instance, a subset of
low-grade endometrioid carcinoma with ER and PR
expression, clearly type I carcinoma, occurs unrelated
to estrogen in the background of atrophic endometrium.
On the other hand, it has been shown that an occasional
papillary serous carcinoma may develop from a preex-
isting endometrioid carcinoma as a result of tumor
progression. These tumors may share the pathologic and
molecular features of types I and II endometrial cancers.
Therefore, in daily practice many endometrial carcinomas
are in the gray zone with overlapping clinical, morpho-
logic, immunohistochemical, and molecular features.
Molecular Genetic Alterations in
Endometrioid (Type I) Carcinoma
Endometrioid carcinoma is characterized by a variety
of genetic alterations, in particular, those affecting pro-
teins bound to the cell membrane and responsible for
cell adhesion and signaling transduction. Currently, the
most frequently altered gene in endometrioid carcinoma
is PTEN, which is located on chromosome 10 and codes
for a protein with tyrosine kinase function [8]. The PTEN
protein has both lipid and protein phosphatase activity.
The lipid phosphatase activity may cause arrest of cell-
cycle progression at G1/S, mediated at least partially
through the upregulation of the cyclin-dependent kinase
inhibitor p27. In addition, agonist-induced apoptosis
is mediated by PTEN through the upregulation of
proapoptotic machinery, involving caspases and BID,
and the downregulation of antiapoptotic proteins, such
as Bcl2. The protein phosphatase activity of PTEN is
involved in the inhibition of focal adhesion formations,
cell spreading, and migration, as well as the inhibition
of growth factor-stimulated MAPK signaling. Therefore,
the combination of the losses of PTEN lipid and protein
phosphatase activity may result in aberrant cell growth
and an escape from apoptosis, as well as abnormal
cell spreading and migration [9]. Up to 83% of
endometrioid carcinomas and 55% of precancerous
lesions reveal altered PTEN, characterized by loss of
expression [10]. Therefore, loss of PTEN function is an
early event in endometrial tumorigenesis that may occur
in response to known endocrine risk factors and offers
an informative immunohistochemical biomarker for pre-
malignant disease. The underlying genetic alteration in
cases with lost PTEN expression and function is mostly
Table 1. Two types of clinicopathologic features of endometrial carcinoma
Type 1 Type 2
Incidence 80% ≤ 20%
Age Pre-/perimenopausal > 60 yr
Histology Endometrioid Serous, clear
Cell differentiation Low grade High grade
Precursor lesion Hyperplastic EM Atrophic EM
Estrogen stimulation Related Unrelated
Clinical behavior Indolent Aggressive
mutation and, less frequently, loss of heterozygosity
(LOH) without mutation [10]. However, promoter
methylation was found in about 20% of tumors with
altered PTEN, most of which were high-stage diseases
[11]. Inactivation of PTEN caused by mutation is asso-
ciated with early stage and favorable survival [12]. The
5-year survival rate is about 80% in those with mutations
compared with 50% in those lacking mutations [12].
Microsatellite instability (MI) is another important
genetic alteration in endometrioid carcinoma and its
variants [13,14], occurring in about 20–45% of tumors
[15]. It is characterized by minor genetic alterations, 
in particular, frame-shift mutations in repetitive DNA
sequences of the genome. Inactivation of the mismatch
repair gene MLH1 by methylation of the promoter
seems to be the most frequent cause of MI in sporadic
endometrioid carcinomas [16,17], followed by loss of
expression of another two mismatch repair genes MSH2
and MSH6 [18,19]. The mechanism for inactivation of
MSH2 is still not clear, since promoter methylation
and mutations are rare [16,20]. MSH6 inactivation
seems to be almost always caused by mutation [21].
MI is associated with PTEN mutation, absence of p53
overexpression, and a favorable outcome. The 5-year
survival rate of those with MI is 77% compared with
48% of negative MI cases [22].
K-ras protooncogene encodes for a small inner
plasma cellular membrane GTPase, functioning as a
molecular switch during cell signaling, and it is largely
related to tumor growth and differentiation. Consti-
tutively activating mutations of the K-ras protooncogene
are present in about 10–30% of endometrioid carcino-
mas [23]. They are predominantly found in exon 1
(codons 12 and 13) and rarely in exon 2 (codon 61)
[24]. The presence of K-ras mutations in 16% of the
cases of endometrial hyperplasia indicates that K-ras
mutations may represent an early event within a subset
of endometrial carcinoma [25]. K-ras mutations have
been found more frequently in MI tumors, suggesting
that both events may occur simultaneously before
clonal expansion [26]. In contrast, K-ras and PTEN
mutations do not seem to concur within the same
tumor [27].
β-catenin mutation is present in about 20% of
endometrioid carcinomas [28]. β-catenin gene is crucial
in cell–cell adhesion through a complex with E-cadherin.
In addition, it is an important member for the signal
transduction pathway (Wnt), which is required for adult
tissue maintenance, and perturbations in Wnt signaling
promote both human degenerative disease and cancer
[29]. The function of β-catenin in endometrioid tumori-
genesis is still unknown; no correlation to MI, K-ras, or
PTEN mutations have been found, suggesting that the
Wnt pathway may play an independent role in endome-
trial cancer [30].
E-cadherin is a transmembrane protein with five
extracellular domains and an intracellular domain that
connects to the actin cytoskeleton through a complex
with the cytoplasmic catenin. Decreased E-cadherin
expression is associated with a loss of cell–cell cohesive
forces and has been shown to precede tumor cell
motility—a characteristic of tumor cell lines with high
metastatic potential [31,32]. Decreased expression of
E-cadherin is found in about 5–40% of endometrioid
carcinoma. E-cadherin negative tumors are more likely
to be poorly differentiated or nonendometrioid, and
are associated with poorer outcome [33–35].
p16 is a tumor suppressor gene located on chromo-
some 9p21. It encodes for a cell cycle regulatory protein
and inactivation of the p16 gene can lead to uncon-
trolled cell growth. In a large population-based study,
loss of p16 expression was found in less than 10% of
endometrioid carcinoma [36]. The underlying mecha-
nism of altered p16 expression is not clear, since neither
methylation nor deletion or mutation is frequently
found [37–40]. Loss of p16 expression is correlated with
K-ras and p53 mutations and is associated with high
stage, high grading, nonendometrioid tumors, and poor
survival [40].
p53 mutations were found in a subset of approxi-
mately 10–20% of endometrioid carcinomas, which were
mostly grade 3 [41]. Grade 1 carcinomas and atypical
hyperplasia seem to lack mutant p53. p53 mutations
are almost always associated with aneuploidy and do
not seem to concur with PTEN mutations in the same
tumor [42].
Her2/neu oncogene codes for a transmembrane
receptor tyrosine kinase involved in cell signaling.
Overexpression of Her2/neu seems to play a role in
10–30% of grades 2 and 3 endometrioid adenocarci-
nomas [43,44]. Therefore, mutations in p53 and the
amplification and overexpression of Her2/neu charac-
terize late events during progression and the dedifferen-
tiation of endometrioid carcinoma [41]. Both alterations
are associated with high grade, advanced disease, and
poor prognosis. Alternatively, these later molecular alter-
ations might also be early events in de novo, occurring 
in poorly differentiated endometrioid carcinomas and
those serous carcinomas developing from endometrioid
carcinomas, based on findings from mixed endometrioid
and serous carcinomas [45], where MI is a rare event,
as are PTEN and K-ras mutations [46].
KAI1 is a metastasis suppressor gene located on
human chromosome 11p11.2. It is a member of the
structurally distinct family of cell surface glycoprotein,
transmembrane 4 protein superfamily. KAI1 was initially
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isolated as a gene that suppressed metastasis of prostate
cancer [47]. In our study, downregulation but no
mutation of KAI1 was found during the progression 
of endometrial cancer, in which most of the studied
cases were endometrioid carcinoma [48]. KAI1 was well
expressed in endometrial hyperplasia but was progres-
sively lost from early stage (27.8%) to metastatic tumors
(71.4%). In addition, patients with KAI1-negative tumors
had a lower survival rate than those with KAI1-positive
or decreased tumors.
Smad4 is a member of the Smad proteins, which are
needed for mediating signals of TGF-β from the cell
surface to the nucleus. Smad4 is also a tumor suppressor
gene for several cancers. Using immunohistochemical
study we noted that Smad4 protein expression was de-
creased progressively with tumor grade [49]. Decreased
Smad4 mRNA was also observed in the endometrioid
carcinomas with myometrial infiltration [50].
Molecular Genetic Alterations in Serous
and Clear Cell (Type II) Carcinoma
The most striking genetic alteration, present in about
90% of serous carcinoma, is p53 mutation [51]. It is
still unresolved as to which carcinogenic influence
causes these frequent p53 mutations. In contrast to
endometrioid carcinoma, MI is extremely rare among
serous carcinoma, as is K-ras and PTEN mutation
[41,52,53]. Thus far, MI has only been detected in mixed
endometrioid and serous carcinoma, but not in pure
serous carcinomas [54]. Other genetic alterations that
seem to occur more frequently in serous than in
endometrioid carcinoma are inactivation of p16 and
overexpression of Her2/neu as previous description.
p16 inactivation was found in about 45% of serous carci-
nomas, including some clear cell carcinomas. Her2/neu
overexpression and gene amplification were found in
about 45% and 70% of serous carcinomas, respectively
[55,56]. Furthermore, negative and reduced E-cadherin
expression occurred in 62% and 87%, respectively, of
serous and clear cell carcinomas [33,57]. However,
alteration and overexpression of β-catenin are rare in
serous carcinoma [30,58]. Clear cell carcinoma has
rarely been studied alone because of the uncommon
occurrence. Based on immunohistochemical results and
mutational analysis, there was evidence that p53 alter-
ations play a minor role compared with serous carci-
noma [7,59]. Since p53 mutation was also infrequently
observed in ovarian clear cell carcinoma comparing to
the other epithelial subtypes [60], it is possible that
the pathogenesis of clear cell carcinoma in the female
genital tract arises from a unique pathway [61]. As in
serous carcinoma, MI and PTEN inactivation are rarely
found in clear cell carcinoma. K-ras mutation is also
absent in this tumor.
Comparison of the major genetic alterations
between types I and II endometrial carcinomas as ana-
lyzed on endometrioid and serous carcinomas, respec-
tively, is seen in Table 2.
Progression Model for Endometrioid
(Type I) Carcinoma
Most of the genetic alterations found in endometrioid
carcinoma seem to occur very early in endometrioid
tumorigenesis, although it is not clear which are asso-
ciated with the earliest changes of malignant transfor-
mation and progression to neoplasia. In atypical
hyperplasia, alterations of PTEN, β-catenin, K-ras, and
MI are present, of which PTEN inactivation occurs in
about 50% of the cases [10]. Methylation of MLH1
promoter was found in adjacent non-neoplastic
endometrium of MI + endometrioid carcinoma [62].
In contrast, p53 mutations, amplification, and overex-
pression of Her2/neu and p16 inactivation are consid-
ered late events during progression and dedifferentiation
Table 2. Comparison of major genetic alterations between type I and type II endometrial carcinomas as analyzed on 
endometrioid and serous carcinomas
Genetic alteration Type I carcinomas (%) Type II carcinomas (%)
PTEN inactivation 50–80 10
Microsatellite instability 20–45 0–5
K-ras mutations 10–30 0–5
β-catenin mutations 20 0–5
p53 mutations 10–20 90
Her2/neu overexpression 10–30 45–80
p16 inactivation 10 40
E-cadherin alteration 10–20 80–90
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of endometrioid carcinoma, since they are predomi-
nantly found in grade 3 tumors, rarely in grade 1 tumors
and are absent in atypical endometrial hyperplasia [43].
On the other hand, it is hypothesized that p53 muta-
tions and Her2/neu amplification might also be early
events in de novo occurring poorly differentiated endo-
metrioid carcinomas, detouring atypical hyperplasia and
low-grade carcinoma on an alternative pathway.
Progression Model for Serous (Type II)
Carcinoma
Mutations of p53 were found in about 80% of endome-
trial EIC, the putative precursor of serous carcinoma,
but in contrast to most serous carcinoma, there is no
LOH at the locus of p53. Thus, it was hypothesized that
p53 mutation of one allele occurs early during the devel-
opment of serous carcinoma’s precursor, whereas loss
of the normal second allele accompanies progression
into serous carcinoma [51]. Another hypothesis is that
serous carcinoma may develop from endometrioid
carcinoma through p53 mutation based on findings in
mixed endometrioid and serous carcinomas [45]. The
alterations of E-cadherin, p16, and Her2/neu seem to
occur during the progression from EIC to serous carci-
noma. It is not clear whether other genetic alterations
that are present in serous carcinoma occur early during
tumorigenesis, since no analyses on EIC exist.
Molecular Genetic Alterations in
Hereditary Endometrial Carcinoma
Endometrial carcinoma is the most common extra-
colonic malignancy in hereditary nonpolyposis colorec-
tal cancer (HNPCC or Lynch syndrome), an autosomal
dominantly inherited disorder of cancer susceptibility
[63]. It was reported that the cumulative incidence of
endometrial cancer in HNPCC was 20% by age 70, com-
pared to 3% in the general population, and the highest
risk years was between age 40 and 60 [64]. Therefore,
endometrial cancer in HNPCC develops at a signifi-
cant earlier age than in the general population. In
addition, more than half of the cases had a second pri-
mary tumor and most of these cancers were colorectal
cancers [65]. To date, the only known cause of HNPCC
is an inherited mutation in one of the following mis-
match repair genes: MLH1, MSH2, MSH6, PMS1, and
PMS2 [66,67]. In endometrial carcinomas, however,
inactivation of the MSH2/MSH6 complex seems to play
a central role in tumorigenesis [68]. The endometrial
carcinomas arising in HNPCC are related to type I
tumors, since they occur at young age and are histolog-
ically of mucinous or endometrioid type [69], but their
pathway is driven by germline mutations and is, thus,
distinctive. In MSH2 mutaion carriers, a high MI status
was already present in endometrial hyperplasia without
atypia [70]. It is thus considered an early event during
tumor development.
In addition to endometrial cancer arising from
HNPCC, occasional families show clustering of endome-
trial cancer alone, without colon or other cancers. This
group of endometrial cancer was termed as familial
site-specific endometrial cancer [71]. One recent study
investigated 23 such families and found that only two
families (8.7%) had germline mutation in MSH6 and
MSH2, respectively [72]. This finding suggests another
as yet unknown etiology in most of the families with
site-specific endometrial cancer.
Conclusion
With the aid of molecular studies, knowledge of the
pathogenesis of endometrial cancer has extensively
broadened over the last decade. Nevertheless, an enor-
mous amount of work remains to be done to clearly
understand the biologic processes behind the develop-
ment of this disease. Recently, using cDNA microarray
technology, the differences in gene expression patterns
between histologic types of endometrial cancer were
identified. [73]. This comprehensive analysis of endome-
trial cancer may help us to understand differences in the
biology and clinical outcome of the different histologic
types. Further stratification of endometrial cancer sub-
types according to their genetic alterations may improve
prognostic impact and provide us with new targets for
treatment.
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